Navigation Links
Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting
Date:3/28/2009

Data provide support for expected Phase 3 program

CRANBURY, N.J., March 28 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today positive results from its ongoing Phase 2 extension study of its investigational drug, Amigal(TM) (migalastat HCL) for Fabry disease. The results will be presented at the American College of Medical Genetics (ACMG) 2009 Annual Meeting in Tampa, FL.

Phase 2 Extension Study Overview:

Twenty-six subjects completed either 12 or 24 weeks of treatment during Phase 2 studies. Twenty-three of the 26 subjects continue to receive treatment in an ongoing extension study designed to evaluate the long term safety and efficacy of Amigal. Ten of the 23 subjects have been on treatment for at least 2 years and 4 subjects have been on treatment for more than 3 years.

Preliminary Results:

Treatment with Amigal was generally well-tolerated, with no drug-related serious adverse events. The most common adverse events were headache, arthralgia and diarrhea.

Subjects identified as responders to Amigal at the completion of the Phase 2 studies continued to maintain elevated levels of the target enzyme (a-Gal A), as measured in white blood cells, and reduced levels of the target substrate (kidney GL-3), as measured in urine.

A reduction of GL-3 levels was also observed in interstitial capillary cells from kidney biopsies. Previously reported Phase 2 results indicated that little to no GL-3 was detected in these cells in most subjects prior to treatment with Amigal. The new data were obtained from the retesting of biopsies using an improved methodology.

Preliminary results from the evaluation of modified doses and a new dosing regimen were also presented.

Derralynn
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
2. Amicus Therapeutics Announces Change to Board of Directors
3. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
4. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
5. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
8. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
9. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
10. Amicus Therapeutics Opens Research Facility in San Diego
11. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /CNW/ - Sunovion Pharmaceuticals ... APTIOM TM (eslicarbazepine acetate) for use as a ... in patients with epilepsy who are not satisfactorily controlled ... for use in patients under 18 years of age. ... common neurological disorders and according to Epilepsy Canada, it ...
(Date:7/10/2014)... July 10, 2014 Deep Knowledge ... Medicine Forum on ‘Commercialising Longevity Research’ and welcomed ... to the London Bioscience Innovation Center for the ... and Aging Analytics Ltd. The meeting highlighted the ... translational research for age-related disease, as well as ...
(Date:7/10/2014)... 2014 OMICS Group’s 5th International conference ... August, 2014 at Double Tree by Hilton Beijing, China ... in Analytical & Bioanalytical research methods only to facilitate ... this occasion, Dr. Srinubabu Gedela, MD of OMICS Group ... a remarkable one in bringing a unique and international ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a firm ... today announced that it has acquired the Slim-Fast brand ... the business. Terms of the transaction were not disclosed. ... meal replacement business that markets ready-to-drink shakes, powders, bars ... America and in the United ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... Aug. 24, 2011 United Therapeutics Corporation (NASDAQ: ... of its FREEDOM-C(2) Phase 3 trial of treprostinil ... formulation of treprostinil, a stable synthetic form of ...  Preliminary analysis demonstrates that the trial did not ...
... Lake, N.Y. New research from the Trudeau Institute ... (LAIV), commonly known as FluMist, elicits protection. The ... Vaccine . The journal article is entitled "Live attenuated ... and was authored by Trudeau Institute scientist Dr. Laura ...
... Mich.---A delicate balance of atomic forces can be exploited ... attribute that,s important for many nanotech applications but hard ... The same type of forces are at work bringing ... supercluster structures in this research are in many ways ...
Cached Biology Technology:FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4Trudeau Institute announces a discovery in how FluMist elicits protection 2Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2
(Date:7/11/2014)... researchers, including scientists from the Max Planck Institute for ... major step in understanding photosynthesis, the process by which ... in its atmosphere and which is therefore crucial for ... The researchers report the first direct visualization of a ... in which a specific protein complex, photosystem II, splits ...
(Date:7/11/2014)... hippocampus, the marginal division of the striatum is ... the impact degree of substance P in the ... Yan Yu and his team, College of Biophotonics, ... staining, that substance P receptor, neurokinin 1 was ... division of normal rats. Unilateral or bilateral injection ...
(Date:7/11/2014)... de Janeiro, Brazil- In the brains of all ... that allows an electric or chemical signal to ... Chemical synapses, which are the most abundant type ... Synapse formation is crucial for learning, memory, perception ... inhibitory synapses critical for brain function. For ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2Blame it on the astrocytes 2
... New Geosphere postings cover using traditional geochemistry ... Volcanic Belt; an investigation of mafic rock samples from ... the southeastern Colorado Plateau of New Mexico and Arizona; ... field and micro-analytical techniques; and an addition to the ...
... from Australia are more positive than negative now with regards ... a "long way to go." Considerable progress has been ... heat that continues to generate smoke from the open mine. ... 11, but there are still "weeks of firefighting ahead" according ...
... the list of the chicken,s most lasting legacies may ... optics that can transmit light with the efficiency of ... The unusual arrangement of cells in a chicken,s eye ... new state of matter known as "disordered hyperuniformity," according ...
Cached Biology News:Geosphere covers Mexico, the Colorado Plateau, Russia, and offshore New Jersey 2Geosphere covers Mexico, the Colorado Plateau, Russia, and offshore New Jersey 3Geosphere covers Mexico, the Colorado Plateau, Russia, and offshore New Jersey 4Geosphere covers Mexico, the Colorado Plateau, Russia, and offshore New Jersey 5Geosphere covers Mexico, the Colorado Plateau, Russia, and offshore New Jersey 6In the eye of a chicken, a new state of matter comes into view 2In the eye of a chicken, a new state of matter comes into view 3In the eye of a chicken, a new state of matter comes into view 4In the eye of a chicken, a new state of matter comes into view 5
Human Norrin Biotinylated Affinity Purified PAb Protein Family: Other Growth Factors, Other Wnt-related Molecules...
...
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Request Info...
Biology Products: